Renal DiseasesNCT06533241
Trends of Renal Biopsy in Pediatric Patients at Tanta University Hospital for 10 Years From 2012 to 2022.
An observational study of Renal Diseases, run by Tanta University at 1 site in Egypt.
Trial summary
This study will be conducted on pediatric patients less than 18 years' old who underwent renal biopsy at Tanta University Hospital from 2012 to 2022. Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Renal Diseases
- What is being tested?
- renal biopsy
- Type of treatment
- Surgery or procedure
- How many people
- 1,000 participants
- Where
- 1 siteEgypt
- Study dates
- 28 Nov 2023to Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: All pediatric patients less than 18 years' old who underwent renal biopsy.
Who may be able to join
- All pediatric patients less than 18 years' old who underwent renal biopsy.
Who cannot join
- no exclusions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Trends of Renal Biopsy in Pediatric Patients at Tanta University Hospital
This study will be conducted on pediatric patients less than 18 years' old who underwent renal biopsy at Tanta University Hospital from 2012 to 2022.
Read the detailed description
This study will be conducted on pediatric patients less than 18 years' old who underwent renal biopsy at Tanta University Hospital from 2012 to 2022.
The data will be collected from records:
- History taking including age and sex.
- Indications for renal biopsy.
- Methods of renal biopsy
- Complications of renal biopsy
- Adequacy of samples
- The results obtained by light microscopy
- The results obtained by electron microscopy, immunofluorescence when indicated
- Conditions
- Renal Diseases
- Being tested
- renal biopsy
- Medical subject headings
- Kidney Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
renal biopsyProcedure or surgery
percutaneous renal biopsy procedure
| Study group | Role | What they receive |
|---|---|---|
| pediatric patients less than 18 years' old who underwent renal biopsy | pediatric patients less than 18 years' old who underwent renal biopsy at Tanta University Hospital from 2012 to 2022. Receives: Procedure: renal biopsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
the indications of renal biopsy
investigate the indications of renal biopsy in pediatric patients at Tanta University Hospital for 10 years from 2012 to 2022
Measured: 3 months
Secondary outcomes (1)
light , electron microscope and immunofluorescence results of renal biopsy
investigate the results of renal biopsy in pediatric patients at Tanta University Hospital for 10 years from 2012 to 2022
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2024
- Study start28 Nov 2023
- Primary completionSep 2024 (estimated)
- Study completionSep 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal DiseasesStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Mabrouk Elghoul, Tanta University
- Investigators
- Sara Mabrouk Mohamed Elghoul, MD, Principal investigator, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06533241
- Sponsor's protocol ID
- 36264PR419/11/23
- Status last verified
- Aug 2024
- First submitted
- 30 Jul 2024
- Last updated
- 6 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Trends of Renal Biopsy in Pediatric Patients at Tanta University Hospital
- ClinicalTrials.gov ID
- NCT06533241
- Acronym / sponsor ID
- 36264PR419/11/23
- Conditions
- Renal Diseases
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 28 Nov 2023 (actual)
- Primary completion
- Sep 2024 (estimated)
- Study completion
- Sep 2024 (estimated)
- First posted
- 1 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will be conducted on pediatric patients less than 18 years' old who underwent renal biopsy at Tanta University Hospital from 2012 to 2022.
Detailed description
This study will be conducted on pediatric patients less than 18 years' old who underwent renal biopsy at Tanta University Hospital from 2012 to 2022.
The data will be collected from records:
- History taking including age and sex.
- Indications for renal biopsy.
- Methods of renal biopsy
- Complications of renal biopsy
- Adequacy of samples
- The results obtained by light microscopy
- The results obtained by electron microscopy, immunofluorescence when indicated
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| pediatric patients less than 18 years' old who underwent renal biopsy | – | Procedure: renal biopsypediatric patients less than 18 years' old who underwent renal biopsy at Tanta University Hospital from 2012 to 2022. |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- All pediatric patients less than 18 years' old who underwent renal biopsy.
Key inclusion criteria (1 listed)
- All pediatric patients less than 18 years' old who underwent renal biopsy.
Key exclusion criteria (1 listed)
- no exclusions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| renal biopsypercutaneous renal biopsy procedure | Procedure or surgery | pediatric patients less than 18 years' old who underwent renal biopsy |
Primary outcome
the indications of renal biopsy
Time frame: 3 months
investigate the indications of renal biopsy in pediatric patients at Tanta University Hospital for 10 years from 2012 to 2022
1 secondary outcome
light , electron microscope and immunofluorescence results of renal biopsy
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Renal Diseases
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sara Mabrouk Mohamed Elghoul, MD principal investigator
Tanta University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Diseases, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the indications of renal biopsy (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2024.